Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

rento's current beliefs and expectations, and should not be regarded as a representation by Sorrento that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Sorrento's businesses; the potential for approval and commercial success of Cynviloq; the scope and validity of patent protection for Sorrento's platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; the potential that Sorrento may require substantial additional funding in order to obtain regulatory approval for and commercialize Sorrento's proprietary G-MAB® fully-human antibody library platform technologies or product candidates; and additional risks set forth in Sorrento's filings with the Securities and Exchange Commission. These forward-looking statements represent Sorrento Therapeutics' judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Sorrento undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.  


'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 ... report is available in its catalogue: ... 2014-2024 http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html ... – discover technological and commercial prospects What ... delivery market? Visiongain,s brand new report shows ...
(Date:8/28/2014)... Pharmatech initiated enrollment for its AccessPPM ... method for matching cancer patients to cancer clinical ... specific cancers, disease staging, and genetic mutations - ... in the first place. The challenge that the ... be well known to the patient or even ...
(Date:8/28/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today updates the timeline for the GMP ... The Company is scheduled to submit ... Food & Drug Administration,s (CFDA) review in the ...
Breaking Medicine Technology:Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... The High Court of Germany ( Bundesgerichtshof ) handed ... in its dispute with the Finnish company Medix Biochemica. The ... associated with Medix,s ActimPROM test is null and void due ... to pay AmniSure® an undisclosed amount to be determined by ...
... -- Chindex International, Inc. ("Chindex") (Nasdaq: CHDX ... products and services in the People,s Republic of China, ... results for the three and nine-month periods ended December ... market closes. Management will host a conference call at ...
Cached Medicine Technology:German High Court Rules in Favor of AmniSure® as New European Guidelines Published 2Chindex International to Report Financial Results for the Three and Nine-Month Periods Ended December 31, 2010 2
(Date:8/29/2014)... Food and Drug Administration (FDA)-approved treatment for decreasing ... effective at reducing fracture risk as other current ... loss. With the use of wide- and small-angle ... out experiments at the U.S. Department of Energy,s ... Laboratory that revealed an additional mechanism underlying raloxifene ...
(Date:8/29/2014)... Francisco, CA (PRWEB) August 30, 2014 ... 10 best web conference providers in the online service ... the list were global leaders Webex, GotoMeeting and Infinite. ... the industry users have to determine which provider is ... Essentially, web conference businesses search for compelling consumer goods ...
(Date:8/29/2014)... 2014 The 8th Annual Paint Columbus Pink® ... a Cause, Pink Pooch Contest, Light of Life Ceremony, Power ... Pink Bow Campaign – all in support of cancer awareness. ... this year…. Paint Columbus Pink Foam and Obstacle Challenge on ... 727 54th Street, Columbus, Georgia 31904. It will be the ...
(Date:8/29/2014)... 29, 2014 After having a double ... had to have breast reconstruction. She found that the ... she decided that there needed to be a solution. ... a woman or man who needs or wants breast ... promotes confidence and peace of mind. Producible in design ...
(Date:8/29/2014)... 2014 University of Western States (UWS), ... announced that Daniel Redwood, DC, director of the human ... the Year,” by the Missouri State Chiropractors Association (MSCA) ... , Patrick Montgomery, DC, president of the MSCA, cited ... Missouri House Task Force for Medicaid Reform, in bringing ...
Breaking Medicine News(10 mins):Health News:Revealing a novel mode of action for an osteoporosis drug 2Health News:Top10InAction Reveals Best Web Conference Providers 2Health News:Paint Columbus Pink Cancer Awareness/Kick-Off Meeting for Anyone Interested in Participating 2Health News:University of Western States Director of Human Nutrition and Functional Medicine Daniel Redwood, DC, named Missouri Educator of the Year by MSCA 2
... June 03, 2010 The John Theurer Cancer Center ... physicians and researchers will present 16 abstracts on treatment ... during the Annual Meeting of American Society of Clinical ... "At the John Theurer Cancer Center, we,re ...
... Americans now have choices ... treatment in the USA, Medical Tourism is the answer. , ... Carlsbad, CA (PRWEB) June 2, 2010 – Website promotes the healthcare options ... USA. , , ,Global Medical Connect is a one stop medical tourism shop to take care ...
... , THURSDAY, June 3 (HealthDay News) -- Fatal medication ... of the inexperience of new medical residents, a new ... July, and those first weeks may be a dangerous ... the University of California, San Diego. , The ...
... say it,s not always that simple, , THURSDAY, June 3 ... in many a parent. But having to incorporate information ... make an already sensitive subject even more complicated. , Yet ... As assisted reproduction technology, in which someone other than the ...
... ... Lake Host Malaria Awareness Soccer Clinic this Thursday for Local Youth as part of White ... ... the United Nations Foundation ’s Nothing But Nets campaign are teaming up to raise ...
... ... research study that provides detailed analyses on health plans’ coverage and management of ... ... Pharmaceuticals Service is an ongoing market research study that provides detailed analyses on ...
Cached Medicine News:Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 2Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 3Health News:Global Medical Connect Launches New Website for the Growing Medical Tourism Industry 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 3Health News:Real Salt Lake Teams Up with Nothing But Nets to Fight Malaria 2Health News:Real Salt Lake Teams Up with Nothing But Nets to Fight Malaria 3Health News:HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications 2Health News:HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications 3
On the wards, on rounds, or at the bedside, clinicians can instantly access authoritative, up-to-date, practical guidelines for the immediate and long-term medical and surgical management of all card...
... Diagnosis & Treatment in Cardiology provides ... and manage patients with cardiac diseases. ... 200 cardiac diseases, each reviewed with ... pertinent information including: differential diagnosis, treatment, ...
... those involved with healthcare decisions to keep ... evidence in their field of interest - ... as the volume of evidence increases. Cochrane ... best single source available for continually updated ...
... Cochrane Reviews enable all those involved with ... with the very latest evidence in their ... becomes harder each year as the volume ... problem by delivering the best single source ...
Medicine Products: